NCT03822117
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patient must have an FGFR 1/2 or 3 gene mutation or translocation
Exclusions: Patients with untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed- see trial for details
https://ClinicalTrials.gov/show/NCT03822117